Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.66
AZN's Cash to Debt is ranked higher than
62% of the 1152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. AZN: 0.66 )
AZN' s 10-Year Cash to Debt Range
Min: 0.35   Max: 8.68
Current: 0.66

0.35
8.68
Equity to Asset 0.34
AZN's Equity to Asset is ranked higher than
51% of the 1034 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. AZN: 0.34 )
AZN' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.59
Current: 0.34

0.31
0.59
Interest Coverage 5.58
AZN's Interest Coverage is ranked higher than
50% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 176.76 vs. AZN: 5.58 )
AZN' s 10-Year Interest Coverage Range
Min: 5.58   Max: 100.5
Current: 5.58

5.58
100.5
F-Score: 4
Z-Score: 2.25
M-Score: -2.88
WACC vs ROIC
8.57%
7.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 7.94
AZN's Operating margin (%) is ranked higher than
72% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. AZN: 7.94 )
AZN' s 10-Year Operating margin (%) Range
Min: 8.19   Max: 38.09
Current: 7.94

8.19
38.09
Net-margin (%) 4.54
AZN's Net-margin (%) is ranked higher than
68% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.10 vs. AZN: 4.54 )
AZN' s 10-Year Net-margin (%) Range
Min: 4.73   Max: 29.72
Current: 4.54

4.73
29.72
ROE (%) 5.56
AZN's ROE (%) is ranked higher than
70% of the 1129 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. AZN: 5.56 )
AZN' s 10-Year ROE (%) Range
Min: 5.9   Max: 45.52
Current: 5.56

5.9
45.52
ROA (%) 2.05
AZN's ROA (%) is ranked higher than
67% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. AZN: 2.05 )
AZN' s 10-Year ROA (%) Range
Min: 2.2   Max: 20.87
Current: 2.05

2.2
20.87
ROC (Joel Greenblatt) (%) 34.41
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.14 vs. AZN: 34.41 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 34.23   Max: 191.23
Current: 34.41

34.23
191.23
Revenue Growth (3Y)(%) -5.70
AZN's Revenue Growth (3Y)(%) is ranked higher than
56% of the 932 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. AZN: -5.70 )
AZN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -54.6   Max: 20
Current: -5.7

-54.6
20
EBITDA Growth (3Y)(%) -30.70
AZN's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 839 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. AZN: -30.70 )
AZN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -40.9   Max: 24.7
Current: -30.7

-40.9
24.7
EPS Growth (3Y)(%) -48.90
AZN's EPS Growth (3Y)(%) is ranked higher than
51% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. AZN: -48.90 )
AZN' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.9   Max: 27.9
Current: -48.9

-48.9
27.9
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AZN Guru Trades in Q2 2014

Louis Moore Bacon 40,000 sh (New)
Paul Tudor Jones 27,100 sh (New)
George Soros 150,000 sh (New)
Mario Gabelli 40,400 sh (New)
Jeremy Grantham 28,000 sh (New)
Jim Simons 1,794,800 sh (+25.60%)
Steven Cohen 225,000 sh (unchged)
Daniel Loeb 1,000,000 sh (unchged)
Steven Cohen 370,800 sh (unchged)
Francis Chou 13,000 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13.00%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
Q3 2014

AZN Guru Trades in Q3 2014

Steven Cohen 611,100 sh (+64.81%)
Mario Gabelli 41,900 sh (+3.71%)
Jim Simons 1,847,100 sh (+2.91%)
Manning & Napier Advisors, Inc 317,180 sh (+2.64%)
Francis Chou 13,000 sh (unchged)
Pioneer Investments 227,221 sh (unchged)
NWQ Managers 64,475 sh (unchged)
George Soros 150,000 sh (unchged)
Steven Cohen 400,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
Charles Brandes Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Stanley Druckenmiller Sold Out
David Dreman 117,003 sh (-0.70%)
John Hussman 173,500 sh (-22.37%)
Louis Moore Bacon 30,000 sh (-25.00%)
» More
Q4 2014

AZN Guru Trades in Q4 2014

Pioneer Investments 754,327 sh (+231.98%)
Jim Simons 2,287,900 sh (+23.86%)
NWQ Managers 66,440 sh (+3.05%)
Francis Chou 13,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
John Hussman 173,500 sh (unchged)
George Soros Sold Out
Louis Moore Bacon Sold Out
Steven Cohen 587,400 sh (-3.88%)
Manning & Napier Advisors, Inc 227,870 sh (-28.16%)
Mario Gabelli 19,900 sh (-52.51%)
David Dreman 28,764 sh (-75.42%)
» More
Q1 2015

AZN Guru Trades in Q1 2015

Francis Chou 13,000 sh (unchged)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 82.80
AZN's P/E(ttm) is ranked higher than
67% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 64.60 vs. AZN: 82.80 )
AZN' s 10-Year P/E(ttm) Range
Min: 6.04   Max: 99.46
Current: 82.8

6.04
99.46
Forward P/E 17.61
AZN's Forward P/E is ranked higher than
88% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 17.61 )
N/A
PE(NRI) 82.40
AZN's PE(NRI) is ranked higher than
71% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.40 vs. AZN: 82.40 )
AZN' s 10-Year PE(NRI) Range
Min: 6.02   Max: 99.71
Current: 82.4

6.02
99.71
P/B 4.78
AZN's P/B is ranked higher than
62% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. AZN: 4.78 )
AZN' s 10-Year P/B Range
Min: 2.3   Max: 6.97
Current: 4.78

2.3
6.97
P/S 3.76
AZN's P/S is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. AZN: 3.76 )
AZN' s 10-Year P/S Range
Min: 1.61   Max: 3.9
Current: 3.76

1.61
3.9
PFCF 22.62
AZN's PFCF is ranked higher than
90% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 22.62 )
AZN' s 10-Year PFCF Range
Min: 6.18   Max: 31.08
Current: 22.62

6.18
31.08
POCF 13.89
AZN's POCF is ranked higher than
91% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.91 vs. AZN: 13.89 )
AZN' s 10-Year POCF Range
Min: 5.35   Max: 20.64
Current: 13.89

5.35
20.64
EV-to-EBIT 49.19
AZN's EV-to-EBIT is ranked higher than
73% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.18 vs. AZN: 49.19 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 55.6
Current: 49.19

4.5
55.6
Shiller P/E 16.43
AZN's Shiller P/E is ranked higher than
96% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 16.43 )
AZN' s 10-Year Shiller P/E Range
Min: 8.07   Max: 25.8
Current: 16.43

8.07
25.8
Current Ratio 0.96
AZN's Current Ratio is ranked lower than
52% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. AZN: 0.96 )
AZN' s 10-Year Current Ratio Range
Min: 0.96   Max: 2.01
Current: 0.96

0.96
2.01
Quick Ratio 0.85
AZN's Quick Ratio is ranked higher than
53% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. AZN: 0.85 )
AZN' s 10-Year Quick Ratio Range
Min: 0.85   Max: 1.69
Current: 0.85

0.85
1.69
Days Inventory 127.43
AZN's Days Inventory is ranked higher than
73% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. AZN: 127.43 )
AZN' s 10-Year Days Inventory Range
Min: 88.45   Max: 291.08
Current: 127.43

88.45
291.08
Days Sales Outstanding 69.57
AZN's Days Sales Outstanding is ranked higher than
78% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.68 vs. AZN: 69.57 )
AZN' s 10-Year Days Sales Outstanding Range
Min: 52.89   Max: 127.8
Current: 69.57

52.89
127.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.90
AZN's Dividend Yield is ranked higher than
97% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. AZN: 3.90 )
AZN' s 10-Year Dividend Yield Range
Min: 1.76   Max: 7.65
Current: 3.9

1.76
7.65
Dividend Payout 2.87
AZN's Dividend Payout is ranked higher than
73% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 2.87 )
AZN' s 10-Year Dividend Payout Range
Min: 0.12   Max: 2.89
Current: 2.87

0.12
2.89
Dividend growth (3y) -2.00
AZN's Dividend growth (3y) is ranked higher than
68% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. AZN: -2.00 )
AZN' s 10-Year Dividend growth (3y) Range
Min: -4.5   Max: 28.3
Current: -2

-4.5
28.3
Yield on cost (5-Year) 5.29
AZN's Yield on cost (5-Year) is ranked higher than
97% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. AZN: 5.29 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.39   Max: 10.38
Current: 5.29

2.39
10.38
Share Buyback Rate 2.60
AZN's Share Buyback Rate is ranked higher than
95% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. AZN: 2.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -144.8
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.26
AZN's Price/DCF (Projected) is ranked higher than
95% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 1.26 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.49
Current: 1.26

0.53
4.49
Price/Median PS Value 1.57
AZN's Price/Median PS Value is ranked higher than
68% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. AZN: 1.57 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.81   Max: 2.38
Current: 1.57

0.81
2.38
Earnings Yield (Greenblatt) 2.00
AZN's Earnings Yield (Greenblatt) is ranked higher than
67% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. AZN: 2.00 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 22.3
Current: 2

1.8
22.3
Forward Rate of Return (Yacktman) -11.03
AZN's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.03 vs. AZN: -11.03 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.1   Max: 27.7
Current: -11.03

-13.1
27.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA, AZN N.Mexico, AZN.Switzerland,
AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
» More Articles for AZN

Headlines

Articles On GuruFocus.com
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 
Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
Brandes International Equity Fund Q3 Commentary Dec 23 2014 
Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 


More From Other Websites
AstraZeneca & Celgene: 'Perplexing' Apr 27 2015
Moody's: Outlook stable for pharmaceuticals; M&A activity to remain strong Apr 27 2015
AstraZeneca Falls on Q1 Earnings Decline, Reiterates View - Analyst Blog Apr 27 2015
Do Green Shoots At AstraZeneca plc Herald Spring Growth At GlaxoSmithKline plc? Apr 27 2015
Number 10 warns of opposition to potential BP bid Apr 26 2015
If its Astra bid was crazy, is Pfizer plotting something even more bonkers? Apr 26 2015
5:56 am AstraZeneca has signed a co-development and commercialization agreement with Innate Pharma Apr 26 2015
Activist Fund Squares Up To RSA In Pay Row Apr 25 2015
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog Apr 24 2015
Europe close: Equities advance as banks and miners rally Apr 24 2015
European stocks close higher awaiting Greek resolution Apr 24 2015
Astrazeneca drug deal hoists Innate Pharma shares to record high Apr 24 2015
Miners and banks push Britain's FTSE towards record highs Apr 24 2015
AstraZeneca forced to defend cancer drug deal with Celgene Apr 24 2015
AstraZeneca profits climb, unveils French tie-up Apr 24 2015
Miners and banks push Britain's FTSE towards record highs Apr 24 2015
European stocks higher awaiting Greece deal update Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK